Drug intelligence / Profile preview

GKIND014A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules

Overview

GKIND014A is a small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor, currently in preclinical development by China Resources Guokang Pharmaceutical. The compound is designed to treat gastric cancer and other gastrointestinal tumors by inhibiting tumor angiogenesis. By blocking VEGFR signaling, GKIND014A prevents the formation of new blood vessels that supply tumors with oxygen and nutrients, thereby suppressing tumor growth and progression. It is currently identified as a lead compound in the developer's oncology pipeline.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on GKIND014A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND014A.

Explore the full profile